4 recruiting, 1 active not recruiting. 5 Phase 3.
By phase and status
Follow Elranatamab: new trials by email Literature Review of Elranatamab trials Research Report on Elranatamab
Trials (filtered) newest first · largest first
All 5 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients Elranatamab, Lenalidomide (Revlimid®), Daratumumab SC (Darzalex) - Multiple Myeloma, Newly Diagnosed | Phase 3 | Recruiting | 824 | 2025-07-09 | 2026-09-30 |
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) Elranatamab, Elotuzumab, Pomalidomide - Multiple Myeloma | Phase 3 | Recruiting | 492 | 2024-02-08 | 2026-11-12 |
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant Elranatamab, Daratumumab, Lenalidomide - Multiple Myeloma | Phase 3 | Recruiting | 1060 | 2022-11-10 | 2026-10-27 |
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant Elranatamab, Lenalidomide - Multiple Myeloma | Phase 3 | Active not recruiting | 854 | 2022-03-25 | 2026-04-16 |
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments Elranatamab, Daratumumab, Pomalidomide - Multiple Myeloma | Phase 3 | Recruiting | 893 | 2021-10-04 | 2026-08-24 |
Conditions studied
Multiple Myeloma (5) · Hematologic Diseases (1) · Neoplasms, Plasma Cell (1)
Sponsors
Pfizer (4) · Intergroupe Francophone du Myelome (1)
Countries
Belgium (5) · France (5) · Australia (4) · Brazil (4) · Canada (4) · Czechia (4) · Finland (4) · Germany (4) · Greece (4) · Italy (4) · Japan (4) · Netherlands (4) · South Korea (4) · Spain (4) · Taiwan (4)
NIH funding
2023 (3)